Key result
Patients continue anticoagulation after bleeding despite unmet decisional needs, driven by trauma from initial VTE.
Why the study?
Contemporary guidelines recommend extended-duration anticoagulation after a first unprovoked VTE, but little was known about whether this recommendation aligns with patient values after an anticoagulant-associated bleeding complication.
Observational (n=14)
No
Patients with unprovoked VTE often choose to continue anticoagulation even after experiencing burdensome bleeding due to fear of VTE recurrence and desire for ongoing specialty care, highlighting the urgent need for structured shared decision-making and patient decision aids.
Answers are grounded in this paper and cite their sources.
Highlights decisional gaps in unprovoked VTE after bleeding; leaves open whether decision aids alter continuation rates.
Background: Contemporary guidelines recommend extended-duration anticoagulation among patients with a first unprovoked venous thromboembolism (VTE). Little is known about whether this recommendation aligns with patient values after a bleeding complication. Objectives: To explore the experiences, values, and decisional needs of patients with unprovoked VTE related to extended-duration treatment after an anticoagulant-associated bleed. Methods: In this descriptive, qualitative study, face to face online semistructured interviews were conducted with patients with unprovoked VTE who had experienced bleeding and continued anticoagulant treatment in one academic hospital in Canada. Data were analyzed using directed content analysis to identify themes. Themes were mapped onto the Ottawa Decisional Support Framework to identify decisional needs. Results: Between September and December 2021, 14 patients were interviewed (age 41-69 years; 9 females). Many patients were not aware of the option to stop anticoagulation and had limited understanding of the decision about treatment duration. Despite the negative quality-of-life impact of clinically relevant bleeding during VTE treatment, the majority continued anticoagulation due to emotional trauma of VTE diagnosis, a perception that bleeding would be more manageable than VTE recurrence, a desire to maintain a connection to subspecialty care or non-VTE related benefits (eg, cancer diagnosis, protection from COVID-19). Patients' decisional needs included lack of choice awareness, inadequate support for participation, lack of personalized risk stratification, and inadequate information on monitoring and managing heavy menstrual bleeding. Conclusion: Despite the impact of anticoagulant-associated bleeding on quality of life, patients preferred continuing with anticoagulation for reasons extending beyond secondary VTE prevention. Effective decision-support interventions are needed to address unmet decisional needs.
No takes yet. Share an insight, caveat, or question.
Winter et al. (2024) conducted an observational in Unprovoked venous thromboembolism (VTE) with anticoagulant-associated bleeding (n=14). Extended-duration anticoagulation after anticoagulant-associated bleeding was evaluated on Patient experiences, values, and decisional needs mapped onto the Ottawa Decisional Support Framework. Patients with unprovoked VTE who suffered bleeding continued anticoagulation due to diagnosis trauma, perceived manageability of bleeding, and subspecialty care access, despite unmet decisional needs.
Synapse has enriched 10 related papers. Consider them for comparative context: